- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03540498
Study of Colonization of Strains L.Plantarum and L.Brevis in the Product AB-DENTALAC Chewing Gum (AB-GUM-2016)
Oral Colonization by Lactobacillus Brevis KABP 052 (CECT 7480) and Lactobacillus Plantarum KABP 051 (CECT 7481): A Randomized, Double-Blinded, Placebo-Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will follow a randomized, double-blind, placebo-controlled design with two groups in parallel, for the evaluation of two different posology models (daily consumption of probiotic gum, with or without previous professional oral cleaning). Probiotics have recently been used to combat oral diseases (plaque control, caries, halitosis, etc.), as a non-invasive natural therapy.
The aim of this study is to assess whether the daily consumption of AB-DENTALAC gum allows the colonization of strains L.plantarum KABP051 (CECT7481) and L.brevis KABP052 (CECT7480) in the oral microbiota, and to confirm the absence of side effects, with the following setup:
- Number of patients to be randomized:40
- Number of visits per patient: 2
The study will determine the index of plaque and gingival index as a measure of oral health. The presence of Lactobacillus in the samples collected by qPCR will also be quantified.
The patient will benefit from a buccal revision and control by a periodontist for 6 weeks. It will also help subsequent patients to obtain a better treatment (if the results are significant). No harm is expected to participate, it is a minimal risk study, with non-invasive exploratory tests and a product suitable for human consumption and marketed in Europe since 2012.
The potential patients to participate in the study will be healthy patients, so if they do not wish to participate they will not need alternative treatment. The objective of the study is to see if the probiotic is able to colonize the mouth in healthy patients, it is not a study to demonstrate the effectiveness of the product.
If there is any serious adverse effect (something totally unexpected being a product with probiotic strains QPS), the patient will be advised to stop taking the product immediately. It is not anticipated that the use of any additional treatment is necessary.
The promoter will provide all the necessary material for the study: 60 cases of placebo chewing gum, 60 cases of probiotic chewing gum, and cleaning material (toothbrush and fluoridated toothpaste) for all patients.
Statistical analysis of bacterial colonization will be performed using Student's T with logarithmic transformation of data if required, considering a two-tailed P <0.05 as significance cut-off.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women and men between 18-55 years.
- Capacity to understand the procedures and implications of the study.
- Gingival Index <1,5 (Löe and Silness, Acta Odontol Scand. 1963. 21:533-51)
- Plaque Index <2,0 (Löe and Silness, Acta Odontol Scand. 1963. 21:533-51)
- Periodontal pocket depth <5 mm
Exclusion Criteria:
- Less than 20 natural teeth
- More than 2 untreated caries at the time of enrollment
- Current orthodontic or periodontal treatment
- Hypersensitivity or allergy to any of the ingredients of the experimental product
- Consumption of antibiotics in the 8 weeks prior to treatment
- Use of probiotics designed to improve oral health, or having consumed them during the 8 weeks prior to the study
- Consumption of any type of probiotic during the 4 weeks prior to the study
- Usual consumption of clorhexidine or other mouthwashes with bactericidal active ingredients during the 30 days before the start of the study
- Pregnant or lactating women
- Participants with chronic diseases (eg, diabetes, kidney problems, cancer) or under chronic treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Probiotics
The volunteers will follow the assigned treatment for 6 weeks (PROBIOTICS_AB-DENTALAC CHEWING GUM.
Orally) , which will consist of the consumption of 2 chewing gums a day.
The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food.
For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth.
Adherence to the treatment will be made by returning the empty containers after 6 weeks.
|
Treatment for 6 weeks, which will consist of the consumption of a chewing gum AB-DENTALAC with 100mg L.plantarum + L.brevis Probiotics blend (5E+8 CFU each at the end of shelf life), b.i.d (morning and evening).
|
Placebo Comparator: Control
The volunteers will follow the assigned treatment for 6 weeks (PLACEBOS CHEWING GUM.
Orally) , which will consist of the consumption of 2 chewing gums a day.
The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food.
For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth.
Adherence to the treatment will be made by returning the empty containers.
|
Treatment for 6 weeks, which will consist of the consumption of a chewing gum placebo, without probiotics strains, b.i.d (morning and evening).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Probiotic colonization of the oral cavity (qPCR)
Time Frame: Change from Baseline assessed 6 weeks after study entry
|
Quantification of L. brevis and L. plantarum by species-specific qPCR in pooled samples of saliva, dental plaque (from the CPI subset) and lingual plaque
|
Change from Baseline assessed 6 weeks after study entry
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression of PII
Time Frame: Change from Baseline assessed 6 weeks after study entry
|
Plaque Index (PlI; Silness and Löe 1964) in the CPI teeth subset, as recorded at the first visit and at the end of the study by the dentist.
|
Change from Baseline assessed 6 weeks after study entry
|
Progression of GI
Time Frame: Change from Baseline assessed 6 weeks after study entry
|
Gingival Index (GI; Löe and Silness 1963) in the CPI teeth subset, as recorded at the first visit and at the end of the study by the dentist.
|
Change from Baseline assessed 6 weeks after study entry
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Jordi Espadaler Mazo, PhD, AB Biotics, SA
- Principal Investigator: Jose Nart Molina, DMD, Clínica Odontológica Nart en Barcelona
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AB-GUM-2016
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Periodontal Disease
-
University of BeykentCompletedPeriodontal Diseases | Periodontal Attachment Loss | Periodontal Inflammation | Periodontal Disease, AVDC Stage 3 | Periodontal Disease, AVDC Stage 4Turkey
-
Universitat Internacional de CatalunyaKing's College London; Universidad de Murcia; Universidad Complutense de Madrid; Universidad de Granada and other collaboratorsRecruitingPeriodontitis | Periodontal Disease, AVDC Stage 3 | Periodontal Disease, AVDC Stage 4Spain
-
Technische Universität DresdenCompletedPeriodontal Disease | Periodontal Attachment LossGermany
-
Aristotle University Of ThessalonikiRecruitingPeriodontal Diseases | Furcation Defects | Periodontal Disease, AVDC Stage 3 | Periodontal Disease, AVDC Stage 4Greece
-
National Institute of Dental and Craniofacial Research...CompletedDental Plaque | Periodontal Disease | Oral Health | Periodontal Disease and CariesUnited States
-
Yuzuncu Yıl UniversityCompletedPeriodontal Disease | Gingival DiseaseTurkey
-
Sheffield Teaching Hospitals NHS Foundation TrustCompletedPeriodontal DiseaseUnited Kingdom
-
National Cheng-Kung University HospitalGrape King Bio Ltd.Completed
-
University Hospitals Cleveland Medical CenterWithdrawn
-
Dentsply InternationalCompletedPeriodontal DiseaseUnited States
Clinical Trials on AB-DENTALAC [Probiotics (study)]
-
AB Biotics, SACompletedModerate HypercholesterolemiaFrance
-
Baskent UniversityCompletedInfant, Premature, Diseases
-
Aga Khan UniversityUnknownGlucose Intolerance | PregnancyPakistan
-
Next Gen Pharma India Pvt. Ltd.Krishnadevaraya College of Dental Sciences & HospitalCompletedChronic PeriodontitisIndia
-
Columbia UniversityNemours Children's Clinic; Johns Hopkins All Children's HospitalCompletedHematopoietic Organs; DisorderUnited States
-
Children's HealthCompletedAppendicitis | Appendicitis; PerforationUnited States
-
AB Biotics, SAHospital de Nens de BarcelonaCompletedSurgery--Complications | Molar, ThirdSpain
-
Fudan UniversityNot yet recruiting